FDA Fast-Tracks Review of Promising Alzheimer's Drug

Thursday, 18 Jul 2013 07:39 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Canadian biopharmaceutical company Transition Therapeutics said the U.S. Food and Drug Administration granted a fast-track status to its Alzheimer's drug, sending its U.S.-listed shares up 33 percent in post-market trading.

A fast track designation by the FDA expedites regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs.
 
The drug, ELND005, currently being tested in a mid-stage trial, treats neuropsychiatric symptoms such as agitation or aggression in Alzheimer's disease.
 
Transition Therapeutics said the drug appeared to decrease the emergence and severity of specific neuropsychiatric symptoms in a previous mid-stage study.
 
About 90 percent of Alzheimer's patients develop neuropsychiatric symptoms and up to 60 percent develop agitation over the course of their disease, the company said.
 
Ireland-based Elan Corp Plc is Transition's marketing and development partner.
Transition Therapeutics' Toronto-listed shares closed at C$3.15 (U.S. $3.02) on Wednesday.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Cheap Eye Medication Effective as Costly Drug: Study

Sunday, 14 Sep 2014 21:21 PM

Injecting Roche's cancer drug Avastin as a cheap eye treatment does not appear to increase deaths or serious side effect . . .

Dissolving Heart Stent Leads to Less Angina

Sunday, 14 Sep 2014 21:09 PM

Abbott's Absorb dissolving heart stent proved as safe and effective one year after being placed in a diseased artery as  . . .

Electrical Shocks Used in Autism Treatment Draw Controversy

Sunday, 14 Sep 2014 10:06 AM

Some cut themselves.Others slam their heads against walls or desks - so hard that one girl detached both retinas and a y . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved